Bell Investment Advisors’s Intellia Therapeutics NTLA Stock Holding History

Bell Investment Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-74	Closed	-$1.28K	–	1903
2025 Q3	$1.28K	Hold	74	–	–	﹤0.01%	1491
2025 Q2	$695	Buy	74 +61	+469%	+$501	﹤0.01%	1685
2025 Q1	$93	Hold	13	–	–	﹤0.01%	1887
2024 Q4	$152	Hold	13	–	–	﹤0.01%	1881
2024 Q3	$268	Sell	13 -41	-76%	-$945	﹤0.01%	1846
2024 Q2	$1.21K	Hold	54	–	–	﹤0.01%	1552
2024 Q1	$1.49K	Buy	54 +20	+59%	+$556	﹤0.01%	1466
2023 Q4	$1.04K	Sell	34 -5	-13%	-$144	﹤0.01%	1583
2023 Q3	$1.23K	Buy	39 +26	+200%	+$1.01K	﹤0.01%	1485
2023 Q2	$531	Sell	13 -42	-76%	-$1.7K	﹤0.01%	1824
2023 Q1	$2.05K	Buy	55 +27	+96%	+$1.06K	﹤0.01%	1253
2022 Q4	$977	Buy	28 +17	+155%	+$808	﹤0.01%	1606
2022 Q3	$1K	Hold	11	–	–	﹤0.01%	1498
2022 Q2	$1K	Buy	+11	New	+$559	﹤0.01%	1518
2021 Q4	$0	Hold	4	–	–	﹤0.01%	1896
2021 Q3	$1K	Buy	+4	New	+$606	﹤0.01%	1485

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bell Investment Advisors's NTLA Position: Q4 2025 in Review

Bell Investment Advisors sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 74 shares — an estimated $1.28K sold.

Bell Investment Advisors first reported a position in NTLA in Q3 2021 and held it in 16 quarters. The position peaked at $2.05K in Q1 2023. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

Bell Investment Advisors reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
Bell Investment Advisors sold 74 Intellia Therapeutics shares in Q4 2025, an estimated $1.28K.
Bell Investment Advisors first reported a position in Intellia Therapeutics in Q3 2021 and held it in 16 quarters.
Bell Investment Advisors's Intellia Therapeutics position peaked at $2.05K in Q1 2023.
293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Bell Investment Advisors's 13F filing for Q4 2025, filed 24 Feb 2026.